ECSP10010233A - Granulación en húmedo que utiliza un agente secuestrante de agua - Google Patents

Granulación en húmedo que utiliza un agente secuestrante de agua

Info

Publication number
ECSP10010233A
ECSP10010233A EC2010010233A ECSP10010233A ECSP10010233A EC SP10010233 A ECSP10010233 A EC SP10010233A EC 2010010233 A EC2010010233 A EC 2010010233A EC SP10010233 A ECSP10010233 A EC SP10010233A EC SP10010233 A ECSP10010233 A EC SP10010233A
Authority
EC
Ecuador
Prior art keywords
wet granulation
sequencing agent
granulation used
water
water sequencing
Prior art date
Application number
EC2010010233A
Other languages
English (en)
Inventor
Thomas Weitao Sun
Ray Lo
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40623940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010233(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of ECSP10010233A publication Critical patent/ECSP10010233A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen tabletas que comprenden formulaciones estables hidrolíticamente de sal disódica de (6-(5-flúor-2-(3,4,5-trimetoxifenilamino)pirimidin-4-ilamino)-2,2-dimetil-3-oxo-2H-pirido[3,2-b][1,4]oxazin-4(3H)-il)metil fosfato (compuesto 1) preparado por un proceso de granulación en húmedo.
EC2010010233A 2007-11-07 2010-06-04 Granulación en húmedo que utiliza un agente secuestrante de agua ECSP10010233A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98623707P 2007-11-07 2007-11-07

Publications (1)

Publication Number Publication Date
ECSP10010233A true ECSP10010233A (es) 2010-07-30

Family

ID=40623940

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010233A ECSP10010233A (es) 2007-11-07 2010-06-04 Granulación en húmedo que utiliza un agente secuestrante de agua

Country Status (34)

Country Link
US (3) US8263122B2 (es)
EP (1) EP2217241B1 (es)
JP (1) JP5567487B2 (es)
KR (2) KR20150129067A (es)
CN (1) CN101998857A (es)
AU (1) AU2008323938B2 (es)
BR (1) BRPI0820389A2 (es)
CA (1) CA2704474C (es)
CO (1) CO6280491A2 (es)
CR (1) CR11476A (es)
CU (1) CU23915B1 (es)
CY (1) CY1122163T1 (es)
DK (1) DK2217241T3 (es)
DO (1) DOP2010000136A (es)
EA (1) EA020210B1 (es)
EC (1) ECSP10010233A (es)
ES (1) ES2672519T3 (es)
HN (1) HN2010000930A (es)
HR (1) HRP20181174T1 (es)
HU (1) HUE039193T2 (es)
IL (1) IL205204A (es)
LT (1) LT2217241T (es)
MX (1) MX2010004733A (es)
MY (1) MY169761A (es)
NI (1) NI201000078A (es)
NZ (1) NZ585913A (es)
PL (1) PL2217241T3 (es)
PT (1) PT2217241T (es)
RS (1) RS57525B1 (es)
SG (1) SG185961A1 (es)
SI (1) SI2217241T1 (es)
TR (1) TR201807879T4 (es)
UA (1) UA102825C2 (es)
WO (1) WO2009061909A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080223392A1 (en) * 2007-03-14 2008-09-18 L'oreal Process for relaxing or straightening hair
GB0814688D0 (en) 2008-08-12 2008-09-17 Knauf Insulation Thermal insulation product
AU2010290829A1 (en) * 2009-09-07 2012-04-26 Douglas Robert Cleverly Granulated anthelmintic preparations and delivery systems
JP2013520501A (ja) * 2010-02-24 2013-06-06 オースペックス ファーマシューティカルズ，インク． チロシンキナーゼのトリメトキシフェニルインヒビター
ES2710423T3 (es) * 2011-07-28 2019-04-25 Rigel Pharmaceuticals Inc Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas
WO2016172053A1 (en) 2015-04-24 2016-10-27 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
US5763172A (en) * 1992-01-21 1998-06-09 Board Of Regents, The University Of Texas System Method of phosphate ester hydrolysis
US5358652A (en) * 1992-10-26 1994-10-25 Ethyl Petroleum Additives, Limited Inhibiting hydrolytic degradation of hydrolyzable oleaginous fluids
WO1999033846A2 (en) * 1997-12-31 1999-07-08 The University Of Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
US6238677B1 (en) * 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
US6716453B1 (en) * 1999-05-20 2004-04-06 Verion, Inc. Method for increasing the active loading of compressible composition forms
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2005526095A (ja) * 2002-03-20 2005-09-02 エラン ファーマ インターナショナル，リミティド 脆砕性の低い急速溶解投与剤型
US20060018972A1 (en) * 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
ITMI20040498A1 (it) * 2004-03-16 2004-06-16 Solvay Solexis Spa Composizioni granulari
ATE451381T1 (de) * 2005-01-19 2009-12-15 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
AU2010286354A1 (en) * 2009-08-31 2012-04-19 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
WO2012064377A1 (en) * 2010-03-29 2012-05-18 Chelsea Therapeutics, Inc. Antifolate compositions

Also Published As

Publication number Publication date
US8263122B2 (en) 2012-09-11
SG185961A1 (en) 2012-12-28
EA020210B1 (ru) 2014-09-30
HN2010000930A (es) 2012-11-12
HRP20181174T1 (hr) 2018-09-21
WO2009061909A2 (en) 2009-05-14
MY169761A (en) 2019-05-15
KR20100088622A (ko) 2010-08-09
AU2008323938A1 (en) 2009-05-14
LT2217241T (lt) 2018-09-10
ES2672519T3 (es) 2018-06-14
MX2010004733A (es) 2010-06-25
UA102825C2 (ru) 2013-08-27
IL205204A (en) 2015-07-30
BRPI0820389A2 (pt) 2015-05-19
CN101998857A (zh) 2011-03-30
EP2217241A2 (en) 2010-08-18
CY1122163T1 (el) 2020-07-31
US8372415B2 (en) 2013-02-12
EA201070570A1 (ru) 2010-10-29
AU2008323938B2 (en) 2014-04-10
EP2217241B1 (en) 2018-04-25
US20130189359A1 (en) 2013-07-25
US20090123539A1 (en) 2009-05-14
RS57525B1 (sr) 2018-10-31
US8652492B2 (en) 2014-02-18
TR201807879T4 (tr) 2018-06-21
DOP2010000136A (es) 2010-09-30
CA2704474A1 (en) 2009-05-14
KR101663838B1 (ko) 2016-10-07
KR20150129067A (ko) 2015-11-18
CU20100089A7 (es) 2011-10-05
CO6280491A2 (es) 2011-05-20
SI2217241T1 (sl) 2018-10-30
JP2011503010A (ja) 2011-01-27
US20120288543A1 (en) 2012-11-15
CA2704474C (en) 2016-04-26
PT2217241T (pt) 2018-06-11
JP5567487B2 (ja) 2014-08-06
WO2009061909A3 (en) 2009-11-05
CR11476A (es) 2010-08-27
HUE039193T2 (hu) 2018-12-28
NZ585913A (en) 2012-06-29
NI201000078A (es) 2011-05-16
DK2217241T3 (en) 2018-08-06
IL205204A0 (en) 2010-12-30
CU23915B1 (es) 2013-07-31
PL2217241T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
ECSP10010233A (es) Granulación en húmedo que utiliza un agente secuestrante de agua
BRPI0412516A (pt) sal isetionato de um seletivo inibidor cdk4
RS53898B1 (en) QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS
RS53574B1 (en) PYROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS
EA200801680A1 (ru) Производные пиримидина, применимые в качестве ингибиторов pi-3 киназы, и способы их применения
ATE359077T1 (de) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
GT200100022A (es) Derivados de nicotinamida benzocondensada-heterociclilo utiles como inhibidores selectivos de las isozimas pde4.
MX2009011755A (es) Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
NZ590777A (en) PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE FOR INHIBITING mTOR
SV2007002359A (es) Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada ref. bhco 41331/sv
BRPI0820308A8 (pt) composições farmacêuticas
BRPI0516242A (pt) compostos tieno-pirimidina tendo atividade fungicida
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
PE20160026A1 (es) Compuestos heterociclicos como agentes para control de plagas
CR10404A (es) Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
EA201491675A1 (ru) Новые вещества
DE602005025979D1 (de) Alkaloid-formulierungen
AR065698A1 (es) Preparacion solida
WO2008059368A3 (en) Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
BR112012031297A2 (pt) formulações de spray oral e métodos para administração de sildenafil
EA200970669A1 (ru) Производные 2-амино-5,7-дигидро-6н-пирроло[3,4-d]пиримидина в качестве ингибиторов hsp-90, предназначенные для лечения рака